We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
Read MoreHide Full Article
Key Takeaways
CRISPR Therapeutics reported Q1 loss of $1.28 per share, wider than estimates, with sales missing forecasts.
CRSP shares fell after hours as results disappointed despite rising Casgevy sales via Vertex partnership.
CRSP boosted cash to $2.44B after note issuance, supporting pipeline expansion and multiple 2026 updates.
CRISPR Therapeutics (CRSP - Free Report) reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago quarter.
Total revenues were $1.46 million in the quarter (comprising $1 million in collaboration revenue and the rest from grant revenues), which significantly missed the Zacks Consensus Estimate of $8.39 million. In the year-ago period, CRSP recorded total revenues of $0.87 million, which comprised only grant revenues.
CRSP Stock Movement
Shares of CRISPR Therapeutics were down in after-market trading yesterday, likely due to the wider-than-expected loss incurred during the quarter.
Year to date, the stock has risen 2% against the industry’s 3% decline.
Image Source: Zacks Investment Research
CRSP Boasts Robust Casgevy Sales Momentum
CRISPR Therapeutics and partner Vertex Pharmaceuticals’ (VRTX - Free Report) CRISPR/Cas9 gene therapy, Casgevy, is approved across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Per the deal terms, Vertex leads global development, manufacturing and commercialization of Casgevy, and splits program costs and profits worldwide with CRISPR Therapeutics in a 60:40 ratio.
Vertex recorded Casgevy sales of about $43 million in the quarter, up from $14.2 million in the year-ago period. This revenue growth was attributed to continued uptake for therapy and reimbursement progress across major regions. Recently, Vertex secured a pricing agreement for therapy in Germany, with final implementation underway.
CRSP Manages Costs While Strengthening Balance Sheet
CRISPR Therapeutics reported research and development (R&D) expenses of $68.6 million in the first quarter of 2026, down 5.4% year over year. The company attributed the decline primarily to lower employee-related costs, including stock-based compensation, reflecting continued efforts to align spending with program priorities.
General and administrative expenses were $17.2 million, down about 11% year over year, also mainly due to lower employee-related costs. Collaboration expense, net, improved to $45.9 million from $57.5 million, driven by an increase in the company’s share of Casgevy sales under the Vertex collaboration economics.
CRSP exited the quarter with $2.44 billion in cash, cash equivalents and marketable securities, up from $1.98 billion at the end of 2025. It said the increase was primarily driven by $585.4 million in net proceeds from the issuance of convertible senior notes in March, partially offset by operating expenses. The higher cash position strengthens the company’s ability to fund operations as it works to broaden its revenue base over time.
Balance sheet metrics also reflected the larger liquidity position, with working capital rising to $2.31 billion and total assets increasing to $2.73 billion as of March 31, 2026. For investors, the higher cash base provides additional flexibility to fund multiple clinical updates expected later in 2026 across Casgevy expansion efforts, zugo-cel studies and liver-directed in vivo programs.
CRSP’s Pipeline Updates
Alongside the quarterly results, CRISPR announced that Vertex has submitted a regulatory filing seeking label expansion for Casgevy in patients aged five to 11 years with SCD and TDT. If this filing is accepted, VRTX intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to 1-2 months.
CRISPR Therapeutics is advancing its investigational CAR-T cell therapy, zugo-cel, across autoimmune disease and hematologic malignancies, with the autoimmune program becoming increasingly central to the near-term pipeline narrative. The company is running two ongoing phase I basket studies across rheumatology and hematology autoimmune indications, supporting a breadth-first strategy as it evaluates activity across multiple diseases. The program recently moved into autoimmune neurologic diseases after the FDA cleared a third phase I study, which has already been initiated.
CRISPR Therapeutics is focusing on in-vivo candidates. It is currently prioritizing the development of CTX310, designed to target ANGPTL3, in an early-stage study for severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia. An update on this study is expected in the second half of 2026.
The company intends to further expand this in-vivo pipeline with more CRISPR-based programs, which include CTX340 (for refractory hypertension), CTX460 (for alpha-1 antitrypsin deficiency [AATD]) and CTX321 (for lipoprotein(a) [Lp(a)]). While a clinical study on CTX340 is expected to start in the first half of 2026, the same for CTX460 is targeted for mid-2026.
The collaboration with Sirius Therapeutics has helped the company diversify its pipeline beyond gene therapies and into RNA therapeutics. Both companies are developing an investigational RNA therapy called CTX611 (formerly SRSD107), in a mid-stage study for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). Top-line data from this study are expected in the second half of 2026.
CRSP’s Zacks Rank
The stock currently carries a Zacks Rank #3 (Hold).
Over the past 30 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have narrowed from 79 cents to 78 cents. CSTL shares have lost 34% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 30 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.78 to $2.79. Over the same period, EPS estimates for 2027 have increased from $3.25 to $3.28. CPRX shares have gained 24% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
Key Takeaways
CRISPR Therapeutics (CRSP - Free Report) reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago quarter.
Total revenues were $1.46 million in the quarter (comprising $1 million in collaboration revenue and the rest from grant revenues), which significantly missed the Zacks Consensus Estimate of $8.39 million. In the year-ago period, CRSP recorded total revenues of $0.87 million, which comprised only grant revenues.
CRSP Stock Movement
Shares of CRISPR Therapeutics were down in after-market trading yesterday, likely due to the wider-than-expected loss incurred during the quarter.
Year to date, the stock has risen 2% against the industry’s 3% decline.
Image Source: Zacks Investment Research
CRSP Boasts Robust Casgevy Sales Momentum
CRISPR Therapeutics and partner Vertex Pharmaceuticals’ (VRTX - Free Report) CRISPR/Cas9 gene therapy, Casgevy, is approved across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Per the deal terms, Vertex leads global development, manufacturing and commercialization of Casgevy, and splits program costs and profits worldwide with CRISPR Therapeutics in a 60:40 ratio.
Vertex recorded Casgevy sales of about $43 million in the quarter, up from $14.2 million in the year-ago period. This revenue growth was attributed to continued uptake for therapy and reimbursement progress across major regions. Recently, Vertex secured a pricing agreement for therapy in Germany, with final implementation underway.
CRSP Manages Costs While Strengthening Balance Sheet
CRISPR Therapeutics reported research and development (R&D) expenses of $68.6 million in the first quarter of 2026, down 5.4% year over year. The company attributed the decline primarily to lower employee-related costs, including stock-based compensation, reflecting continued efforts to align spending with program priorities.
General and administrative expenses were $17.2 million, down about 11% year over year, also mainly due to lower employee-related costs. Collaboration expense, net, improved to $45.9 million from $57.5 million, driven by an increase in the company’s share of Casgevy sales under the Vertex collaboration economics.
CRSP exited the quarter with $2.44 billion in cash, cash equivalents and marketable securities, up from $1.98 billion at the end of 2025. It said the increase was primarily driven by $585.4 million in net proceeds from the issuance of convertible senior notes in March, partially offset by operating expenses. The higher cash position strengthens the company’s ability to fund operations as it works to broaden its revenue base over time.
Balance sheet metrics also reflected the larger liquidity position, with working capital rising to $2.31 billion and total assets increasing to $2.73 billion as of March 31, 2026. For investors, the higher cash base provides additional flexibility to fund multiple clinical updates expected later in 2026 across Casgevy expansion efforts, zugo-cel studies and liver-directed in vivo programs.
CRSP’s Pipeline Updates
Alongside the quarterly results, CRISPR announced that Vertex has submitted a regulatory filing seeking label expansion for Casgevy in patients aged five to 11 years with SCD and TDT. If this filing is accepted, VRTX intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to 1-2 months.
CRISPR Therapeutics is advancing its investigational CAR-T cell therapy, zugo-cel, across autoimmune disease and hematologic malignancies, with the autoimmune program becoming increasingly central to the near-term pipeline narrative. The company is running two ongoing phase I basket studies across rheumatology and hematology autoimmune indications, supporting a breadth-first strategy as it evaluates activity across multiple diseases. The program recently moved into autoimmune neurologic diseases after the FDA cleared a third phase I study, which has already been initiated.
CRISPR Therapeutics is focusing on in-vivo candidates. It is currently prioritizing the development of CTX310, designed to target ANGPTL3, in an early-stage study for severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia. An update on this study is expected in the second half of 2026.
The company intends to further expand this in-vivo pipeline with more CRISPR-based programs, which include CTX340 (for refractory hypertension), CTX460 (for alpha-1 antitrypsin deficiency [AATD]) and CTX321 (for lipoprotein(a) [Lp(a)]). While a clinical study on CTX340 is expected to start in the first half of 2026, the same for CTX460 is targeted for mid-2026.
The collaboration with Sirius Therapeutics has helped the company diversify its pipeline beyond gene therapies and into RNA therapeutics. Both companies are developing an investigational RNA therapy called CTX611 (formerly SRSD107), in a mid-stage study for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). Top-line data from this study are expected in the second half of 2026.
CRSP’s Zacks Rank
The stock currently carries a Zacks Rank #3 (Hold).
CRISPR Therapeutics AG Price
CRISPR Therapeutics AG price | CRISPR Therapeutics AG Quote
Stocks to Consider
Some better-ranked stocks include Castle Biosciences (CSTL - Free Report) and Catalyst Pharmaceuticals (CPRX - Free Report) . While CSTL sports a Zacks Rank #1 (Strong Buy) at present, CPRX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have narrowed from 79 cents to 78 cents. CSTL shares have lost 34% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 30 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.78 to $2.79. Over the same period, EPS estimates for 2027 have increased from $3.25 to $3.28. CPRX shares have gained 24% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.